The natural history of lymphangioleiomyomatosis: Markers of severity, rate of progression and prognosis

Lymphatic Research and Biology

Volumn 8, Issue 1, 2010, Pages 9-19

  Taveira DaSilva, Angelo M ^a   Pacheco Rodriguez, Gustavo ^a   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; MATRIX METALLOPROTEINASE; TUBERIN; VASCULOTROPIN;

ABDOMINAL BLEEDING; ADIPOCYTE; ANGIOMYOLIPOMA; AUTOSOMAL DOMINANT INHERITANCE; BENIGN TUMOR; BLOOD; CANCER GROWTH; CARDIOPULMONARY EXERCISE TEST; CELL PROLIFERATION; CHYLE; CHYLOTHORAX; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; FORCED EXPIRATORY VOLUME; GAS EXCHANGE; HAMARTOMA; HUMAN; HYPOXEMIA; LUNG CYST; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LYMPHANGIOLEIOMYOMATOSIS; METASTASIS; PNEUMOTHORAX; PRIORITY JOURNAL; PROGNOSIS; REVIEW; URINE;

DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77949798248     PISSN: 15396851     EISSN: None     Source Type: Journal    
DOI: 10.1089/lrb.2009.0024     Document Type: Review

References (99)

1. Kitaichi M, Nishimura K, Harumi I, Izumi T. Pulmonary lymphangiomyomatosis: A report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995;151:527-533.
2. Sullivan EJ. Lymphangioleiomyomatosis: A review. Chest 1998;114:1689-1703.
3. Johnson S. Lymphangioleiomyomatosis: Cclinical features, management and basic mechanisms. Thorax 1999;54:254-264.
4. Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999;115:1041-1052.
5. Urban TJ, Lazor R, Lacronique J, et al. Pulmonary lymphangioleiomyomatosis: A study of 69 patients. Medicine 1999;78:321-337.
6. Johnson S, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000;55:1052-1057.
7. Ferrans VJ, Yu ZX, Nelson WK, et al. Lymphangioleiomyomatosis (LAM). A review of clinical and morphological features. J Nippon Med Sch 2000;67:311-329.
8. Matsui K, Tatsuguchi A, Valencia J, et al. Extrapulmonary lymphangioleiomyomatosis (LAM): Clinicopathologic features in 22 cases. Hum Pathol 2000;31:1242-1248.
9. Ryu JH, Moss J, Beck GJ, et al. The NHLBI Lymphangioleiomyomatosis Registry: Characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006;173:105-111.
10. Glassberg MK: Lymphangioleiomyomatosis. Clin Chest Med 2004;25:573-582.
11. Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000;75:591-594.
12. Moss J, Avila N, Barnes PM, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001;163:669-671.
13. Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001;164:661-668.
14. The European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-1315.
15. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann NY Acad Sci 1991;615:125-127.
16. McCormack FX. Lymphangioleiomyomatosis: A clinical update. Chest. 2008;133:507-516.
17. Berger U, Khaghani A, Pomerance A, et al. Pulmonary lymphangioleiomyomatosis and steroid receptors. Am J Clin Pathol 1990;93:609-614.
18. Ohori NP, Yousem SA, Sonmez-Alpan E, Colby TV. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol 1991;96:529-535.
19. Valencia JC, Pacheco-Rodriguez G, Carmona AK, et al. Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis. Am J Respir Cell Mol Biol. 2006; 35:40-47.
20. Valencia JC, Matsui K, Bondy C, et al. Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis. J Investig Med 2001; 49:421-433.
21. Pacheco-Rodriguez G, Steagall WK, Crooks DM, et al. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res 2007;67:10573-10581.
22. Pacheco-Rodriguez G, Kumaki F, Steagall WK, et al. Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J Immunol 2009;182:1270-1277.
23. Smolarek TA, Wessner LL, McCormack FX, et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998;62:810-815.
24. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000;97: 6085-6090.
25. Knudson AG: Hereditary cancer: Two hits revisited. J Cancer Res Clin Oncol 1996;122:135-140.
26. Bittmann I, Rolf B, Amann G, Lohrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: New insights into pathogenesis. Human Pathol 2003;34:95-98.
27. Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangioleiomyomatosis after transplantation. Am J Respir Crit Care Med 2003;167:976-982.
28. Karbowniczek M, Yu J, Henske EP. Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Path 2003:162:491-500.
29. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004:101:17462-17467.
30. Henske EP. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 2003;38:376-381.
31. Avila NA, Dwyer AJ, Rabel A, Moss J. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: Comparison of CT features. Radiology 2007;242:277-285.
32. Almoosa KF, Ryu JH, Mendez J, et al. Management of pneumothorax in lymphangioleiomyomatosis. Effects on recurrence and lung transplantation complications. Chest 2006;129:1274-1281.
33. Ryu JH, Doerr CH, Fisher SD, et al. Chylothorax in lymphangioleiomyomatosis. Chest 2003;123:623-627.
34. Avila NA, Kelly JA, Chu SC, et al. Lymphangioleiomyomatosis: Abdominopelvic CT and US findings. Radiology 2000;216:147-153.
35. Jaiswal VR, Baird J, Fleming J, Miller DS, Sharma S, Molberg K: Localized retroperitoneal lymphangioleiomyomatosis mimicking malignancy. A case report and review of the literature. Arch Pathol Lab Med 2003;127:879-882.
36. Llopis I, Arandiga R, Real E, et al. Lymphangiomyomatosis mimicking an abdominal lymphoma. Hematologica 2002; 87:EIM23.
37. Lu H-C, Wang J, Tsang Y-M, et al. Lymphangioleiomyomatosis initially presenting with abdominal pain. A case report. J Clin Imag 2003;27:166-170.
38. Wong Y-Y, Yeung T-K, Chu WC-W. Atypical presentation of lymphangioleiomyomatosis as acute abdomen: CT diagnosis. AJR 2003;181:284-285.
39. Avila NA, Bechtle J, Dwyer AJ, et al. Lymphangioleiomyomatosis: CT of diurnal variation of lymphangioleiomyomas. Radiology 2001;221:415-421.
40. Avila NA, Dwyer AJ, Murphy-Johnson DV, et al. Sonography of lymphangioleiomyoma in lymphangioleiomyomatosis: Demonstration of diurnal variation in lesion size. AJR 2005; 184:459-464.
41. Avila NA, Kelly JA, Chu SC, et al. Lymphangioleiomyomatosis: Abdominopelvic CT and US findings. Radiology 2000;216:147-153.
42. Bissler JJ, Kingswood JC. Renal angiomyolipomata: Kidney Intl 2004;66:924-934.
43. Sooriakumaran P, Gibbs P, Coughlin G, et al. Angiomyolipomata: Challenges, solutions, and future prospects based on over 100 cases treated. BJU Int. 2009 Jun 2. [Epub ahead of print]. PMID: 19493268.
44. Taveira-DaSilva AM, Hedin CJ, Stylianou MP, et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001;164:1072-1076.
45. Cornog JL, Enterline HT. Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytoma. Cancer 1966;19:1909-1930.
46. Silversteen EF, Ellis K, Wolff M, Jaretzki A. Pulmonary lymphangiomyomatosis. Am J Roentgenol 1974;120:832-850.
47. Corrin B, Liebow AA. Friedman PJ. Pulmonary lymphangioleiomyomatosis: A review. Am J Pathol 1975;79:348-367.
48. Carrington CB, Cugell DW, Gaensler EA, et al. Lymphangioleiomyomatosis. Physiologic-pathologic-radiologic correlations. Am Rev Respir Dis 1977;116:977-995.
49. Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis: Clinical course in 32 patients. N Engl J Med 1990; 323:1254-1260.
50. Kalassian KG, Doyle R, Kao P, et al. Lymphangioleiomyomatosis: New insights. Am J Respir Crit Care Med 1997;155: 1183-1186.
51. Cohen MM, Pollock-BarZiv S, Johnson SR. Emerging clinical picture of lymphangioleiomyomatosis. Thorax 2005;60:875-879.
52. Taveira-Dasilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004;126:1867-1874.
53. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2003;168: 1427-1431.
54. Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Path 2001;25:479-484.
55. Avila NA, Chen CC, Chu SC, et al. Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology 2000;214:441-446.
56. Avila NA, Dwyer AJ, Murphy-Johnson DV, et al. Lymphangioleiomyomatosis: Correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology 2002;223:189-197.
57. Crausman RS, Lynch DA, Mortensen RL, et al. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangiomyomatosis. Chest 1996;109:131-137.
58. Paciocco G, Uslenghi E, Bianchi A, et al. Diffuse cystic lung diseases. Correlation between radiologic and functional status. Chest 2004;125:135-142.
59. Crausman RS, Jennings CA, Mortensen RL, et al. Lymphangioleiomyomatosis: The pathophysiology of diminished exercise capacity. Am J Respir Crit Care Med 1996;153: 1368-1376.
60. Schmithorst VJ, Altes TA, Young LR, et al. Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: Initial results in lymphangioleiomyomatosis. AJR Am J Roentgenol 2009;192:1037-1044.
61. Hayashida M, Seyama K, Inoue Y, et al. The epidemiology of lymphangioleiomyomatosis in Japan: A nationwide crosssectional study of presenting features and prognostic factors. Respirology 2007;12:523-530.
62. Taveira-Dasilva AM, Steagall WK, Rabel A, et al. Reversible airflow obstruction in lymphangioleiomyomatosis. Chest. 2009 May 15. [Epub ahead of print]. PMID: 19447921
63. Taveira-DaSilva AM, Hathaway OM, Sachdev V, et al. Pulmonary artery pressure in lymphangioleiomyomatosis: An echocardiographic study. Chest 2007;132:1573-1578.
64. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:1150-1157.
65. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006;174:803-809.
66. Nagy B, Nabrady Z, Nemes Z. Pulmonary lymphangiomyomatosis in a preadolescent girl. N Engl J Med 1998; 338:473-474.
67. Meysman M, Noppen M, Herregodts P, Vincken W. A patient with seizures, hemoptysis and dyspnoea. Eur Respir J 1995;8:1433-1434.
68. Badawi RA, Geddes DM. Exertional hemoptysis: LAM and TSC. Thorax 2003;58:460-463.
69. Yamamoto K, Anzai F, Kusajima K, et al. Acute respiratory failure with gross hemoptysis in a patient with lymphangioleiomyomatosis as part of tuberous sclerosis complex. Intern Med 2004;43:755-758.
70. Glasgow CG, Taveira-DaSilva AM, Darling TN, Moss J. Lymphatic involvement in lymphangioleiomyomatosis. Ann NY Acad Sci. 2008;1131:206-214.
71. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis in lymphangioleiomyomatosis. Its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol 2004;28:1007-1016.
72. Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006;4:143-152.
73. Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 2008;358:199-200.
74. Glasgow CG, Avila NA, Lin JP, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009;135:1293-1300.
75. Steagall WK, Glasgow CG, Hathaway OM, et al. Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol 2007;293:L800-808.
76. Taveira-Dasilva AM, Burstein D, Hathaway OM, et al. Pneumothorax after air travel in lymphangioleiomyomatosis, Idiopathic pulmonary fibrosis, and sarcoidosis. Chest 2009;136:665-670.
77. Johnson SR, Whale CI, Hubbard RB, et al. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 2004;59:800-803.
78. Lazor R, Valeyre D, Lacronique J, et al. Groupe d'Etudes et de Recherche sur les Maladies ''Orphelines'' Pulmonaires. Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. Respir Med 2004;98:536-541.
79. Burrows B, Lebowitz MD, Camilli AE, Knudson RJ. Longitudinal changes in forced expiratory volume in one second in adults. Methodologic considerations and findings in healthy nonsmokers. Am Rev Respir Dis 1986;133:974-980.
80. Sherrill D, Enright PL, Kaltenborn WT, Lebowitz MD. Predictors of longitudinal change in diffusing capacity over 8 years. Am J Respir Crit Care Med 1999;160:1883-1887.
81. Dowson LJ, Guest PJ, Stockley RA. Longitudinal changes in physiological, radiological, and health status measurements in a1-antitripsin deficiency and factors associated with decline. Am J Respir Crit Care Med 2001;164:1805-1809.
82. Ji RC. Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. Lymphat Res Biol 2006;4:83-100.
83. Folkman J. Angiogenesis inhibitors. A new class of drugs. Cancer Biol Ther 2003;2: S127-S133.
84. Chang L, Kaipainin A, Folkman J. Lymphangiogenesis. New mechanisms. Ann NY Acad Sci 2002;979:111-119.
85. Hayashi T, Fleming MV, Stetler-Stevenson WG, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Human Pathol 1997;28: 1071-1078.
86. Matsui K, Takeda K, Yu Z-X, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000; 124:267-275.
87. Krymskaya VP, Shipley JM. Lymphangioleiomyomatosis. A complex tale of serum response factor-mediated tissue inhibitor of metalloproteinase-3 regulation. Am J Respir Cell Mol Biol 2003;28:546-550.
88. Zhe X, Yang Y, Jakkaraju S, Schuger L. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2003;28:504-511.
89. Papakonstantinou E, Dionyssopoulos A, Aletras AJ, et al. Expression of matrix metalloproteinases and their endogenous tissue inhibitors in skin lesions from patients with tuberous sclerosis. J Am Acad Dermatol 2004;51:526-533.
90. Odajima N, Betsuyaku T, Nasuhara Y, et al. Matrix metalloproteinases in blood from patients with LAM. Respir Med 2009;103:124-129.
91. Saikali Z, Singh G. Doxycycline and other tetracyclines in the treatment of bone metastasis. Anti-Cancer Drugs 2003;14:773-778.
92. Richardson M, Wong D, Lacroix S, et al. Inhibition by doxycycline of angiogenesis in the chicken chorioallantoic membrane (CAM). Cancer Chemother Pharmacol 2005;56: 1-9.
93. Onoda T, Ono T, Dhar DK, et al. Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int J Cancer 2005;118:1309-1315.
94. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 2006;324:2621-2622.
95. Marhaba R, Zöller M. CD44 in cancer progression: Adhesion, migration and growth regulation. J Mol Histol 2004; 35:211-231.
96. Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45.
97. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56.
98. Li S, Takeuchi F, Wang JA, et al. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. J Exp Med 2005;202:617-624.
99. Yu JJ, Robb VA, Morrison TA, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci USA 2009;106:2635-2640.